MCM
NBIX icon

Marsico Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Marsico Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19,507
Closed -$2.69M – 65
2024
Q2 		$2.69M Hold
19,507
– – 0.08% 54
2024
Q1 		$2.69M Sell
19,507
-40,816
-68% -$5.57M 0.09% 58
2023
Q4 		$7.95M Hold
60,323
– – 0.31% 43
2023
Q3 		$6.79M Sell
60,323
-8,318
-12% -$876K 0.29% 44
2023
Q2 		$6.47M Sell
68,641
-82,298
-55% -$8.04M 0.26% 45
2023
Q1 		$15.3M Sell
150,939
-1,000
-0.7% -$104K 0.72% 29
2022
Q4 		$18.1M Buy
+151,939
New +$17.8M 0.94% 26

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Marsico Capital Management's NBIX Position: Q3 2024 in Review

Marsico Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 19,507 shares — an estimated $2.69M sold.

Marsico Capital Management first reported a position in NBIX in Q4 2022 and held it in 7 quarters. The position peaked at $18.1M in Q4 2022. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • Marsico Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
  • Marsico Capital Management sold 19,507 Neurocrine Biosciences shares in Q3 2024, an estimated $2.69M.
  • Marsico Capital Management first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 7 quarters.
  • Marsico Capital Management's Neurocrine Biosciences position peaked at $18.1M in Q4 2022.
  • 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Marsico Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.